Molecular Formula | C15H21F3N2O2 |
Molar Mass | 318.33 |
Density | 1.16±0.1 g/cm3(Predicted) |
Melting Point | 120-122.5°C |
Boling Point | 370.6±52.0 °C(Predicted) |
Flash Point | 177.9°C |
Solubility | Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 1.1E-05mmHg at 25°C |
Appearance | Oil |
Color | Colourless |
pKa | pKa 8.7 (Uncertain) |
Storage Condition | Sealed in dry,2-8°C |
In vivo study | Fluvoxamine (DU-23000) is effective in inhibiting 5-ht uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine. Fluvoxamine (DU-23000) appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted. Fluvoxamine (DU-23000) was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement. |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
biological activity | Fluvoxamine (DU-23000) is a serotonin reabsorption inhibitor with antidepressant activity. |
target | SSRIs. |